Mitochondrial Benzodiazepine Receptors Regulate Steroid

Total Page:16

File Type:pdf, Size:1020Kb

Mitochondrial Benzodiazepine Receptors Regulate Steroid Proc. Nati. Acad. Sci. USA Vol. 86, pp. 9813-9816, December 1989 Biochemistry Mitochondrial benzodiazepine receptors regulate steroid biosynthesis (peripheral-type benzodiazepine receptor function/cholesterol transport/adrenocortical cells) ALEXEY G. MUKHIN*, VASSILIOS PAPADOPOULOSt, ERMINIO COSTA*t, AND KARL E. KRUEGER*t *Fidia43eorgetown Institute for the Neurosciences and tDepartment of Anatomy and Cell Biology, Georgetown University School of Medicine, 3900 Reservoir Road, Washington, DC 20007 Contributed by Erminio Costa, October 5, 1989 ABSTRACT Recent observations on the steroid synthetic steroid biosynthetic pathway, occurs in mitochondria where capability within the brain open the possibility that benzodi- PBRs are associated with the outer mitochondrial membrane azepines may influence steroid synthesis in nervous tissue (15, 16). Consequently, several groups have demonstrated through interactions with peripheral-type benzodiazepine rec- that benzodiazepines can influence steroid production in ognition sites, which are highly expressed in steroidogenic cells several steroidogenic systems (17-19). and associated with the outer mitochondrial membrane. To To investigate whether PBRs play a central role in steroid examine this possibility nine molecules that exhibit a greater production, we have used the well-characterized Y-1 adreno- than 10,000-fold difference in their affinities for peripheral- cortical cell line as a model system (20, 21). The data type benzodiazepine binding sites were tested for their effects presented here strongly support a role for PBR in the regu- on a well-established steroidogenic model system, the Y-1 lation of steroidogenesis. One might infer that the complex mouse adrenal tumor cell line. 4'-Chlorodiazepam, PK 11195, central actions of various benzodiazepines could include and PK 14067 stimulated steroid production by 2-fold in Y-1 effects on neurosteroid production mediated through cen- cells, whereas diazepam, flunitrazepam, zolpidem, and PK trally located mitochondrial PBRs. 14068 displayed a lower (1.2- to 1.5-fold) maximal stimulation. In contrast, clonazepam and flumazenil did not stimulate steroid synthesis. The potencies of these compounds to inhibit METHODS 3H-labeled PK 11195 binding to peripheral-type benzodi- Cells. The Y-1 mouse adrenal tumor cell line used in these azepine recognition sites correlated (r = 0.985) with their studies was obtained from American Type Culture Collec- potencies to stimulate steroid production. Similar rindings were tion. Stock cultures were grown in modified Waymouth's observed in bovine and rat adrenocortical cell preparations. MB752/1 medium containing 20 mM Hepes, NaHCO3 (1.2 These results suggest that ligands of the peripheral-type ben- g/liter), 15% (vol/vol) horse serum, and 2.5% (vol/vol) fetal zodiazepine recognition site acting on this mitochondrial re- calf serum (pH 7.4). Before use, the cells were washed for ceptor can enhance steroid production. This action may con- three 30-min periods with serum-free medium to eliminate tribute specificity to the pharmacological profile of drugs serum components that may interfere with the assays and preferentially acting on the benzodiazepine recognition site then incubated as indicated in the presence of drugs under associated with the outer membrane of certain mitochondrial investigation. Bovine fasciculata-reticularis and adrenocor- populations. tical cells from adult Sprague-Dawley rats (300 g) were prepared as described (22). Benzodiazepines elicit their primary therapeutic actions in Radioligand Binding Assays. Y-1 cell cultures were scraped the central nervous system through specific binding sites on from the flasks (75 mm2) in 5 ml of Kreb's buffer (8, 29), -y-aminobutyric acid (GABA)-gated chloride channels (1). In dispersed by repetitive pipetting, and centrifuged at 1200 x addition to these sites another class of binding sites for in Kreb's benzodiazepines was identified in peripheral tissues (2) and g for 5 min. The cell pellets were resuspended has been referred to as peripheral-type benzodiazepine rec- buffer and larger cellular aggregates were allowed to settle for ognition sites (PBRs). PBRs are also abundant in neural tissue 5 min. The finely dispersed cell suspensions were taken for (3, 4) where they appear to be preferentially associated with further experimentation. astroglial cells (5). Since the physiological role ofPBRs is not Binding assays were performed in a total volume of 250- presently known, the effects resulting from benzodiazepine 400 ,l of Kreb's buffer containing 3H-labeled PK 11195 [1-(2- interactions with PBRs in peripheral tissues and in the brain chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline- are poorly characterized. Ligands that can bind to the PBR carboxamide] (0.07-20 nM) with 5 ,g of cellular protein. with high affinity have been reported to induce convulsions Incubations were conducted at 37°C for 30 min and bound (6) and exhibit proconflict actions (7, 8). The mechanisms by radioligand was collected by filtration through Whatman which these behavioral effects are generated remain unclear. GF/C filters and rapidly washed four times with 5 ml of 25 The central nervous system can synthesize steroids (9, 10). mM Tris-HCl (pH 7.4) containing 1 ,M PK 11195. Radioac- In another set of investigations, steroids were demonstrated tivity was determined by liquid scintillation counting. Non- to be potent modulators oftype A GABA (GABAA) receptors specific binding was measured in the presence of 10 ,uM (11, 12), implying a physiological role ofsteroids as regulators nonradioactive PK 11195. of GABAergic transmission. These findings are significant Measurement of Steroid Production. These experiments when one considers that PBRs are extremely abundant in were performed with the Y-1 cells plated in 12 x 22 mm wells steroidogenic cells (13, 14). Furthermore, metabolism of cholesterol to pregnenolone, the first intermediate in the Abbreviations: PBR, peripheral-type benzodiazepine recognition site; GABA, y-aminobutyric acid; PK 11195, 1-(2-chlorophenyl)- N-methyl-N-(1-methylpropyl)-3-isoquinolinecarboxamide; PK The publication costs of this article were defrayed in part by page charge 14067 and PK 14068, (-)- and (+)-N,N-diethyl-2-methyl-3-[4-(2- payment. This article must therefore be hereby marked "advertisement" fhenyl)quinolinyllpropanamide, respectively. in accordance with 18 U.S.C. §1734 solely to indicate this fact. To whom reprint requests should be addressed. 9813 Downloaded by guest on September 27, 2021 9814 Biochemistry: Mukhin et al. Proc. Natl. Acad. Sci. USA 86 (1989) and incubated for the times shown in a final volume of 1 ml of serum-free medium at 370C. At the end of the incubation 100 period the cell medium was saved, centrifuged at 1500 x g for 10 min, and stored at -20'C until use. Steroid production was cn determined by measuring 20a-hydroxyprogesterone, the c c main steroid product of these cells (20, 21), using a radioim- .-4 4-J m c munoassay with an antibody donated by G. Nieswender 0 (Colorado State University, Fort Collins). Cortisol and cor- u CD) ticosterone, indices for steroid production in bovine and rat adrenocortical preparations, respectively, were also mea- L) L sured by radioimmunoassay using commercial kits (Baxter n Scientific Products, McGaw Park, IL, and Endocrine Sci- ences, Tarzana, CA, respectively). Analysis of the radioim- munoassay data was performed using the IBM-PC RIA DATA a, -10 -9 -8 -7 -6 -5 -4 REDUCTION program (version 4.1) from Jaffe (Silver Spring, CD, Log [Ligand], M MD). Protein Measurements. Protein was quantitated by the method of Bradford (23) using bovine serum albumin as a 100 standard. B C 80 RESULTS 4-i i U) a Binding of PBR Ligands in Y-1 Cells. Preliminary experi- cn ments to measure 3H-labeled PK 11195 binding in Y-1 cells at CL 370C demonstrated rapid association kinetics reaching equi- I ) 60 -0 librium within 15 min, which was stable for at least 2 hr and fully reversible by adding excess PK 11195 (data not shown). 'C, Scatchard analysis of 3H-labeled PK 11195 binding in Y-1 C'\ cells revealed a single class of recognition sites with a 400 t _ 3 , dissociation constant of 1.8 nM and a Bma, of 54 pmol/mg of -10 -9 -8 -7 -6 -5 -4I protein (Fig. 1). The high density of PBRs in Y-1 total cell membranes is consistent with the abundance reported (24) in Log [Ligand], M rat adrenal mitochondrial preparations. FIG. 2. Binding specificity of PBRs and stimulation of ste- Nine ligands, exhibiting a range greater than four orders of roidogenesis in Y-1 cells. (A) Potencies of nine compounds to magnitude in their affinities for PBRs, were examined for compete against 3H-labeled PK 11195 (0.8 nM) for binding in Y-1 their potencies to inhibit 3H-labeled PK 11195 binding to Y--1 cells. (B) Secretion of 20a-hydroxyprogesterone (20a-OH- cells at 370C (Fig. 2A). These compounds demonstrated a Progesterone) was measured in cultures of Y-1 cells treated for 4 hr rank order of ligand displacement potency (PK 11195 > PK with various concentrations of ligand as indicated. A, PK 11195; *, 14067 > 4'-chlorodiazepam > zolpidem > PK 14608, diaze- PK 14067; E, 4'-chlorodiazepam; O, zolpidem; o, PK 14068; *, pam, flunitrazepam > clonazepam, flumazenil), which is diazepam; A, flunitrazepam; x, clonazepam; *, flumazenil. Curves consistent with reports (16) on PBRs from rat tissues {PK were generated by nonlinear regression analysis of the data. 14067 and PK 14068, (-)- and (+)-N,N-diethyl-2-methyl- 14068 (25). Also at 37°C, benzodiazepines, 4'-chlorodiaz- 3-[4-(2-phenyl)quinolinyl]propanamide, respectively; these epam, diazepam, and flunitrazepam showed a relatively low compounds are referred to in ref. 25 as (-)- and (+)-N,N- potency compared to PK 11195, which is in agreement with diethyl-a-methyl-2-phenyl-4-quinoline propanamide|. In par- a report (26) that demonstrated that the binding of benzodi- ticular it should be noted that PK 14067 was more than two azepines to PBRs is a temperature-sensitive enthalpy-driven orders of magnitude more potent than its stereoisomer PK process.
Recommended publications
  • Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors
    International Journal of Molecular Sciences Article Neonatal Clonazepam Administration Induced Long-Lasting Changes in GABAA and GABAB Receptors Hana Kubová 1,* , Zde ˇnkaBendová 2,3 , Simona Moravcová 2,3 , Dominika Paˇcesová 2,3, Luisa Rocha 4 and Pavel Mareš 1 1 Institute of Physiology, Academy of Sciences of the Czech Republic, 14220 Prague, Czech Republic; [email protected] 2 Faculty of Science, Charles University, 12800 Prague, Czech Republic; [email protected] (Z.B.); [email protected] (S.M.); [email protected] (D.P.) 3 National Institute of Mental Health, 25067 Klecany, Czech Republic 4 Pharmacobiology Department, Center of Research and Advanced Studies, Mexico City 14330, Mexico; [email protected] * Correspondence: [email protected]; Tel.: +420-2-4106-2565 Received: 31 March 2020; Accepted: 28 April 2020; Published: 30 April 2020 Abstract: Benzodiazepines (BZDs) are widely used in patients of all ages. Unlike adults, neonatal animals treated with BZDs exhibit a variety of behavioral deficits later in life; however, the mechanisms underlying these deficits are poorly understood. This study aims to examine whether administration of clonazepam (CZP; 1 mg/kg/day) in 7–11-day-old rats affects Gama aminobutyric acid (GABA)ergic receptors in both the short and long terms. Using RT-PCR and quantitative autoradiography, we examined the expression of the selected GABAA receptor subunits (α1, α2, α4, γ2, and δ) and the GABAB B2 subunit, and GABAA, benzodiazepine, and GABAB receptor binding 48 h, 1 week, and 2 months after treatment discontinuation. Within one week after CZP cessation, the expression of the α2 subunit was upregulated, whereas that of the δ subunit was downregulated in both the hippocampus and cortex.
    [Show full text]
  • Appendix D: Important Facts About Alcohol and Drugs
    APPENDICES APPENDIX D. IMPORTANT FACTS ABOUT ALCOHOL AND DRUGS Appendix D outlines important facts about the following substances: $ Alcohol $ Cocaine $ GHB (gamma-hydroxybutyric acid) $ Heroin $ Inhalants $ Ketamine $ LSD (lysergic acid diethylamide) $ Marijuana (Cannabis) $ MDMA (Ecstasy) $ Mescaline (Peyote) $ Methamphetamine $ Over-the-counter Cough/Cold Medicines (Dextromethorphan or DXM) $ PCP (Phencyclidine) $ Prescription Opioids $ Prescription Sedatives (Tranquilizers, Depressants) $ Prescription Stimulants $ Psilocybin $ Rohypnol® (Flunitrazepam) $ Salvia $ Steroids (Anabolic) $ Synthetic Cannabinoids (“K2”/”Spice”) $ Synthetic Cathinones (“Bath Salts”) PAGE | 53 Sources cited in this Appendix are: $ Drug Enforcement Administration’s Drug Facts Sheets1 $ Inhalant Addiction Treatment’s Dangers of Mixing Inhalants with Alcohol and Other Drugs2 $ National Institute on Alcohol Abuse and Alcoholism’s (NIAAA’s) Alcohol’s Effects on the Body3 $ National Institute on Drug Abuse’s (NIDA’s) Commonly Abused Drugs4 $ NIDA’s Treatment for Alcohol Problems: Finding and Getting Help5 $ National Institutes of Health (NIH) National Library of Medicine’s Alcohol Withdrawal6 $ Rohypnol® Abuse Treatment FAQs7 $ Substance Abuse and Mental Health Services Administration’s (SAMHSA’s) Keeping Youth Drug Free8 $ SAMHSA’s Center for Behavioral Health Statistics and Quality’s (CBHSQ’s) Results from the 2015 National Survey on Drug Use and Health: Detailed Tables9 The substances that are considered controlled substances under the Controlled Substances Act (CSA) are divided into five schedules. An updated and complete list of the schedules is published annually in Title 21 Code of Federal Regulations (C.F.R.) §§ 1308.11 through 1308.15.10 Substances are placed in their respective schedules based on whether they have a currently accepted medical use in treatment in the United States, their relative abuse potential, and likelihood of causing dependence when abused.
    [Show full text]
  • Introduced B.,Byhansen, 16
    LB301 LB301 2021 2021 LEGISLATURE OF NEBRASKA ONE HUNDRED SEVENTH LEGISLATURE FIRST SESSION LEGISLATIVE BILL 301 Introduced by Hansen, B., 16. Read first time January 12, 2021 Committee: Judiciary 1 A BILL FOR AN ACT relating to the Uniform Controlled Substances Act; to 2 amend sections 28-401, 28-405, and 28-416, Revised Statutes 3 Cumulative Supplement, 2020; to redefine terms; to change drug 4 schedules and adopt federal drug provisions; to change a penalty 5 provision; and to repeal the original sections. 6 Be it enacted by the people of the State of Nebraska, -1- LB301 LB301 2021 2021 1 Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2 2020, is amended to read: 3 28-401 As used in the Uniform Controlled Substances Act, unless the 4 context otherwise requires: 5 (1) Administer means to directly apply a controlled substance by 6 injection, inhalation, ingestion, or any other means to the body of a 7 patient or research subject; 8 (2) Agent means an authorized person who acts on behalf of or at the 9 direction of another person but does not include a common or contract 10 carrier, public warehouse keeper, or employee of a carrier or warehouse 11 keeper; 12 (3) Administration means the Drug Enforcement Administration of the 13 United States Department of Justice; 14 (4) Controlled substance means a drug, biological, substance, or 15 immediate precursor in Schedules I through V of section 28-405. 16 Controlled substance does not include distilled spirits, wine, malt 17 beverages, tobacco, hemp, or any nonnarcotic substance if such substance 18 may, under the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.
    [Show full text]
  • Slipping a Mickey? Facts Around Drugs, Alcohol and Sexual Assault
    Slipping a Mickey? Facts around drugs, alcohol and sexual assault DR CATHY STEPHENSON OCTOBER 2011 Slipping a Mickey? Phrase coined in late 19th century Chicago barman Mickey Finn used “knock-out” drops to incapacitate and rob his patrons Probably used chloral hydrate Centuries old practise – other drugs in historical literature include alcohol, barbiturates and scopolamine Recently much media coverage of “date rape” drugs and “drink-spiking” Case 1 18 yo girl, seen 7 hours post sexual assault Party, 5 RTDs in 2.5 hours – left one open on the table Shortly after felt “strange” Taken home by friend’s father In car, forced oral and vaginal penetration Diazepam found on hair samples, but not urine Case 2 16 year old girl Seen 6 months after SA Risk-taking behaviour prompted disclosure ETOH + marijuana + antidepressant Much more common scenario Case 3 23 year old girl Seen 20 hours after sexual assault In town with friends Drinking Offered a ride home Raped in car outside her flat DFSA? Victims subjected to non-consensual sexual activity while they are incapacitated or unconscious through the effect of alcohol or drugs (1) Thereby prevented from resisting and unable to give consent Ingestion can be voluntary, involuntary or both DFSA may be “proactive” or “opportunistic”(2) So how often does it really happen? No reliable data in literature Reporting of SA in general very low 21% of females and almost 5% of males in Australia report a lifetime history of sexual coercion(3) Analysis of 1200 urine samples from sexual
    [Show full text]
  • Identification and Determination of Flunitrazepam and Its Metabolites in Blood by Gas Chromatography
    Chem. Anal. (Warsaw), 49, 71 (2004) Identification and Determination of Flunitrazepam and Its Metabolites in Blood by Gas Chromatography by Zofia Ch³obowska1, Czes³awa wiegoda1, Pawe³ Kocielniak1,2* and Wojciech Piekoszewski1 1 Institute of Forensic Research, ul. Westerplatte 9, 31033 Cracow 2 Faculty of Chemistry, Jagiellonian University, ul. R. Ingardena 3, 30060 Cracow Key words: flunitrazepam, metabolites, gas chromatography Analytical method for the isolation of flunitrazepam and its metabolites (desmethyl- flunitrazepam and 7-amino-flunitrazepam) from blood involving liquid-liquid extraction with diethyl ether, diisopropyl ether and toluene-isoamyl alcohol mixture (95:5) has been developed. In the latter case the extraction yield approached 80%. The analysis of the com- pounds was performed using gas chromatograph with electron capture detector, and a HP1 column. The developed method allowed one to determine flunitrazepam and its metabolites at the level as low as few nanograms. Opracowano metodê analityczn¹ pozwalaj¹c¹ na ekstrakcyjne wyizolowanie flunitrazepamu i jego metabolitów (desmetyloflunitrazepamu i 7-aminoflunitrazepamu) z krwi przy u¿yciu eteru dietylowego, eteru diizpropylowego lub mieszaniny toluenu z alkoholem izoamylowym (95:5). W ostatnim przypadku osi¹gniêto wydajnoæ na poziomie 80%. Do analizy wymie- nionych substancji zastosowano chromatografiê gazow¹ z detektorem wychwytu elektronów oraz kolumnê HP1. Opracowana metoda pozwala wykrywaæ zawartoæ flunitrazepamu i jego metabolitów we krwi na poziomie kilku nanogramów. * Corresponding author. E-mail: [email protected] 72 Z. Ch³obowska, C. wiegoda, P. Kocielniak and W. Piekoszewski Flunitrazepam (Rohypnol), the fluoro derivative of benzodiazepine, is a sedative and hypnotic drug. It is easily absorbed from alimentary tract and undergoes biotrans- formation via N-dimethylation, hydroxylation and reduction with moderate rapidity [1].
    [Show full text]
  • Bioanalytical Studies of Designer Benzodiazepines
    From DEPARTMENT OF LABORATORY MEDICINE Karolinska Institutet, Stockholm, Sweden BIOANALYTICAL STUDIES OF DESIGNER BENZODIAZEPINES Madeleine Pettersson Bergstrand Stockholm 2018 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Eprint AB © Madeleine Pettersson Bergstrand, 2018 ISBN 978-91-7831-063-0 Front page illustration: Sandra Eriksson Bioanalytical studies of designer benzodiazepines THESIS FOR DOCTORAL DEGREE (Ph.D.) The thesis will be defended at 4X, Alfred Nobels allé 8, Huddinge Friday, May 25, 2018 at 09.00 a.m. By Madeleine Pettersson Bergstrand Principal Supervisor: Opponent: Prof. Anders Helander Ass. Prof. Elisabeth Leere Øiestad Karolinska Institutet Oslo University Hospital Department of Laboratory Medicine Department of Forensic Sciences Division of Clinical Chemistry Clinic for Laboratory medicine Co-supervisor: Examination Board: Prof. Olof Beck Prof. Åsa Emmer Karolinska Institutet KTH Royal Institute of Technology Department of Laboratory Medicine Department of Chemistry Division of Clinical Pharmacology Division of Applied Physical Chemistry Docent Stefan Borg Karolinska Institutet Department of Clinical Neuroscience Docent Pierre Lafolie Karolinska Institutet Department of Medicine Division of Clinical Epidemiology ABSTRACT The fast appearance of benzodiazepine analogues, referred to as new psychoactive substance (NPS) or designer benzodiazepines, requires the continuous update of detection methods in order to keep up with the latest drugs on the recreational drug market. Moreover, as usually only limited information on toxicity and excretion patterns of these new drugs exists, this needs to be evaluated to report on adverse effects and to determine suitable targets for drug testing. Urine drug testing usually involves screening using immunoassay followed by confirmation of positive screening results using mass spectrometric (MS) methods.
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]
  • Product Monograph
    PRODUCT MONOGRAPH PrPROPOFOL Propofol Injectable Emulsion, BP 1% w/v 10 mg/mL Intravenous Emulsion – Anaesthetic - Sedative Baxter Corporation Date of Revision: Mississauga, Ontario September 29, 2017 L5N 0C2 Submission Control No: 207653 PROPOFOL Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................8 DRUG INTERACTIONS ..................................................................................................13 DOSAGE AND ADMINISTRATION ..............................................................................14 OVERDOSAGE ................................................................................................................21 ACTION AND CLINICAL PHARMACOLOGY ............................................................21 STORAGE AND STABILITY ..........................................................................................25 DOSAGE FORMS, COMPOSITION AND PACKAGING .............................................25
    [Show full text]
  • Drug-Facilitated Sexual Assault in the U.S
    The author(s) shown below used Federal funds provided by the U.S. Department of Justice and prepared the following final report: Document Title: Estimate of the Incidence of Drug-Facilitated Sexual Assault in the U.S. Document No.: 212000 Date Received: November 2005 Award Number: 2000-RB-CX-K003 This report has not been published by the U.S. Department of Justice. To provide better customer service, NCJRS has made this Federally- funded grant final report available electronically in addition to traditional paper copies. Opinions or points of view expressed are those of the author(s) and do not necessarily reflect the official position or policies of the U.S. Department of Justice. AWARD NUMBER 2000-RB-CX-K003 ESTIMATE OF THE INCIDENCE OF DRUG-FACILITATED SEXUAL ASSAULT IN THE U.S. FINAL REPORT Report prepared by: Adam Negrusz, Ph.D. Matthew Juhascik, Ph.D. R.E. Gaensslen, Ph.D. Draft report: March 23, 2005 Final report: June 2, 2005 Forensic Sciences Department of Biopharmaceutical Sciences (M/C 865) College of Pharmacy University of Illinois at Chicago 833 South Wood Street Chicago, IL 60612 ABSTRACT The term drug-facilitated sexual assault (DFSA) has been recently coined to describe victims who were given a drug by an assailant and subsequently sexually assaulted. Previous studies that have attempted to determine the prevalence of drugs in sexual assault complainants have had serious biases. This research was designed to better estimate the rate of DFSA and to examine the social aspects surrounding it. Four clinics were provided with sexual assault kits and asked to enroll sexual assault complainants.
    [Show full text]
  • Laws 2021, LB236, § 4
    LB236 LB236 2021 2021 LEGISLATIVE BILL 236 Approved by the Governor May 26, 2021 Introduced by Brewer, 43; Clements, 2; Erdman, 47; Slama, 1; Lindstrom, 18; Murman, 38; Halloran, 33; Hansen, B., 16; McDonnell, 5; Briese, 41; Lowe, 37; Groene, 42; Sanders, 45; Bostelman, 23; Albrecht, 17; Dorn, 30; Linehan, 39; Friesen, 34; Aguilar, 35; Gragert, 40; Kolterman, 24; Williams, 36; Brandt, 32. A BILL FOR AN ACT relating to law; to amend sections 28-1202 and 69-2436, Reissue Revised Statutes of Nebraska, and sections 28-401 and 28-405, Revised Statutes Cumulative Supplement, 2020; to redefine terms, change drug schedules, and adopt federal drug provisions under the Uniform Controlled Substances Act; to provide an exception to the offense of carrying a concealed weapon as prescribed; to define a term; to change provisions relating to renewal of a permit to carry a concealed handgun; to provide a duty for the Nebraska State Patrol; to eliminate an obsolete provision; to harmonize provisions; and to repeal the original sections. Be it enacted by the people of the State of Nebraska, Section 1. Section 28-401, Revised Statutes Cumulative Supplement, 2020, is amended to read: 28-401 As used in the Uniform Controlled Substances Act, unless the context otherwise requires: (1) Administer means to directly apply a controlled substance by injection, inhalation, ingestion, or any other means to the body of a patient or research subject; (2) Agent means an authorized person who acts on behalf of or at the direction of another person but does not include a common or contract carrier, public warehouse keeper, or employee of a carrier or warehouse keeper; (3) Administration means the Drug Enforcement Administration of the United States Department of Justice; (4) Controlled substance means a drug, biological, substance, or immediate precursor in Schedules I through V of section 28-405.
    [Show full text]
  • Focus on Benzodiazepines
    Graylands Hospital Drug Bulletin Focus on Benzodiazepines North Metropolitan Health Service – Mental Health March 2015 Vol 22 No.1 ISSN 1323–1251 The Non -BZD hypnotics such as zolpidem and Introduction zopiclone (Z-drugs) are more selective for the alpha-1 subclass which seems to drive sleepiness but not anti-anxiety. Benzodiazepines (BZDs) are one of the most commonly prescribed medications for the treatment Table 1: BZDs and relative half-lives9,10 of insomnia and anxiety. 1 They are also frequently used to treat psychiatric emergencies, epilepsy, severe muscle spasm, acute alcohol withdrawal, Drug name Half -life (hours) anaesthesia and intensive care. Short -acting Triazolam 2 However, the use of BZDs is often controversial as Alprazolam 6-12 they are widely acknowledged to be addictive and Oxazepam 4-15 withdrawal symptoms can occur after 4-6 weeks of Temazepam 8-22 continuous use. This had led to the recommendation Medium -acting that they should not be used as hypnotics or Bromazepam 10 -20 anxiolytics for longer than 4 weeks. 2 In older age, Lorazepam 10 -20 BZDs also have serious adverse effects, including increased risk of falls, road traffic accidents and Long -acting 3,4 Clobazam 12 -60 cognitive impairment. Clonazepam 18 -50 More recently the risks of long term BZD use have Diazepam 20 -100 received greater focus with new evidence Flunitrazepam 18 -26 demonstrating a link between BZD use and the Nitrazepam 15 -38 5 development of Alzheimer’s disease and also 6 increased risk of mortality. Benzodiazepine use in Psychiatry Given the wide spread usage of these medications and the associated risk, this bulletin reviews BZDs Sleep disorders with particular emphasis upon adverse effects, dependence and abuse potential.
    [Show full text]
  • Function of Y-Aminobutyrate Type a Receptors R
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 3658-3662, April 1995 Neurobiology Mutant mice lacking the y isoform of protein kinase C show decreased behavioral actions of ethanol and altered function of y-aminobutyrate type A receptors R. ADRON HARRIS*, SUSAN J. MCQUILKIN*, RICHARD PAYLORt, ASA ABELIOVICHt, SUSUMU TONEGAWA§, AND JEANNE M. WEHNERt *Denver Veterans Affairs Medical Center and Department of Pharmacology, University of Colorado Health Sciences Center, Denver, CO 80262-0236; tlnstitute for Behavioral Genetics and School of Pharmacy, University of Colorado, Boulder, CO 80309; tCenter for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139; and §Howard Hughes Medical Institute at the Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139 Contributed by Susumu Tonegawa, January 18, 1995 ABSTRACT Calcium/phospholipid-dependent protein The role of PKC in the function of GABAA receptors is also kinase (protein kinase C, PKC) has been suggested to play a controversial. Activation of PKC by phorbol esters markedly role in the sensitivity of y-aminobutyrate type A (GABAA) inhibits function of GABAA receptors expressed in oocytes receptors to ethanol. We tested a line of null mutant mice that (13-15) but has less effect on native GABAA receptors ofbrain lacks the 'y isoform of PKC (PKCy) to determine the role of membranes (14, 16). In contrast, the function of recombinant this brain-specific isoenzyme in ethanol sensitivity. We found GABAA receptors expressed in fibroblasts is enhanced by that the mutation reduced the amount of PKCy immunore- catalytically active PKC (17). activity in cerebellum to undetectable levels without altering Thus, the questions of whether GABAA receptor function is the levels ofthe a, 8j3, or Pu isoforms ofPKC.
    [Show full text]